Eli Lilly has entered an oncology research and licensing agreement with privately held biotech company Stipple Bio that could generate as much as $5.9 billion in payments, as the drugmaker works to broaden its cancer business beyond diabetes and obesity medicines.
Under the agreement, Lilly will gain access to Stipple Bio’s technology for identifying molecules that can differentiate cancer cells from healthy tissue. The approach is intended to support the development of treatments that target tumors more precisely, although the partnership itself does not establish that any resulting therapy will be safe, effective or ultimately reach patients.
Terms include milestones and royalties
Stipple Bio said the deal includes an upfront payment, an equity investment from Lilly and aggregate research, development and commercial milestone payments of up to $5.9 billion. The biotech company will also be eligible for tiered royalties on sales if medicines created through the collaboration reach the market.
| Deal element | Terms reported |
|---|---|
| Upfront payment | Included; amount not disclosed |
| Lilly investment | Equity investment; amount not disclosed |
| Milestone payments | Up to $5.9 billion in aggregate |
| Sales royalties | Tiered royalties if products reach the market |
The companies did not disclose the value of the upfront payment or the size of Lilly’s equity investment. Lilly declined to comment beyond its announcement of the agreement, while Stipple Bio disclosed the financial structure of the collaboration.
Lilly builds its cancer pipeline
The partnership adds to Lilly’s effort to expand its oncology portfolio as the company seeks additional growth outside its blockbuster medicines for diabetes and obesity. Its marketed cancer treatments include Verzenio, used in breast cancer, and Jaypirca, used in blood cancer.
Lilly is also advancing experimental cancer medicines across several categories, including targeted therapies, antibody-drug conjugates and immuno-oncology treatments. The Stipple agreement gives the company access to another technology platform while leaving the timing and outcome of any potential Lilly-developed products uncertain.
Stipple’s lead program is preclinical to the reported trial stage
Stipple Bio, which is based in Cambridge, Massachusetts, is developing its own precision-oncology pipeline. Its lead candidate, STP-100, is expected to enter an early-stage clinical trial in early 2027 for solid tumors, including pancreatic cancer.
- The collaboration focuses on molecules designed to distinguish cancer cells from healthy tissue.
- Stipple Bio’s potential compensation includes payments tied to research, development and commercial milestones.
- STP-100 is expected to begin an early-stage trial in solid tumors in early 2027.
That expected trial represents an early point in the development process. Any future progress would depend on research results, clinical testing and regulatory review, as well as the companies’ decisions about whether to advance particular programs.